Free-IgE as a Predictor of Responsiveness to Omalizumab in Oral Corticosteroid-Dependent Asthma Patients

To date, no biomarkers have been found that are able to predict the clinical response to omalizumab. The aim of this study was to assess whether blood concentration of free Immunoglobulin E (IgE) can predict response to treatment with this monoclonal antibody. In a group of patients who were candida...

ver descrição completa

Detalhes bibliográficos
Autores: Domingo, Christian, Monserrate, Daniel-Ross, Ollert, Markus, Pomares, Xavier, Forné Izquierdo, Carles, Del Estal, Jorge, Amengual, María José
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10459.1/468789
Acesso em linha:https://doi.org/10.3390/ijms26072852
https://hdl.handle.net/10459.1/468789
http://hdl.handle.net/10459.1/468789
Access Level:acceso abierto
Palavra-chave:Biomarker
Blood IgE
Clinical response
Free IgE
Omalizumab
Predictor capacity
Severe asthma
id ES_c3efb025914801b2bddaba1dcfbc502e
oai_identifier_str oai:recercat.cat:10459.1/468789
network_acronym_str ES
network_name_str España
repository_id_str
spelling Free-IgE as a Predictor of Responsiveness to Omalizumab in Oral Corticosteroid-Dependent Asthma PatientsDomingo, ChristianMonserrate, Daniel-RossOllert, MarkusPomares, XavierForné Izquierdo, CarlesDel Estal, JorgeAmengual, María JoséBiomarkerBlood IgEClinical responseFree IgEOmalizumabPredictor capacitySevere asthmaTo date, no biomarkers have been found that are able to predict the clinical response to omalizumab. The aim of this study was to assess whether blood concentration of free Immunoglobulin E (IgE) can predict response to treatment with this monoclonal antibody. In a group of patients who were candidates for omalizumab treatment, forced spirometry and blood IgE were measured at entry and at each six-month visit, and free-IgE blood concentrations were measured at month 6. At month 18, the OMADORE protocol was applied. The complete follow-up lasted 30 months. Patients were considered responders if they met at least one of the following criteria: increase in forced expiratory volume in one second (FEV) at the follow-up visit compared to baseline; reduction in corticosteroid dose at the last visit compared to baseline; reduction in omalizumab dose at the follow-up visit; a positive score on the composite index combining all three criteria. The biomarker used to predict treatment response was the free IgE value and the percentage of free IgE to total IgE measured at visit 1, after six months of omalizumab treatment. The percentage of responders varied according to the parameter used (FEV, omalizumab, corticosteroid dose, and the composite index; 45.2%, 64.5%, 48.4%, and 77.4%, respectively). IgE blockade was around 97% both for the group as a whole and for the subgroups. There were no differences in free IgE values nor in the ratio of free IgE to total IgE between responders and non-responders. These results confirm that there is a group of patients who may benefit from the reduction/withdrawal of omalizumab. Determination of free IgE six months after initiation of omalizumab treatment does not discriminate between responders and non-responders.MDPI2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://doi.org/10.3390/ijms26072852https://hdl.handle.net/10459.1/468789http://hdl.handle.net/10459.1/468789reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.3390/ijms26072852International Journal of Molecular Sciences, 2025, vol. 26, núm. 7, 2852cc-by (c)The Authors, 2025Attribution 4.0 Internationalinfo:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/4.0/oai:recercat.cat:10459.1/4687892026-05-29T05:05:01Z
dc.title.none.fl_str_mv Free-IgE as a Predictor of Responsiveness to Omalizumab in Oral Corticosteroid-Dependent Asthma Patients
title Free-IgE as a Predictor of Responsiveness to Omalizumab in Oral Corticosteroid-Dependent Asthma Patients
spellingShingle Free-IgE as a Predictor of Responsiveness to Omalizumab in Oral Corticosteroid-Dependent Asthma Patients
Domingo, Christian
Biomarker
Blood IgE
Clinical response
Free IgE
Omalizumab
Predictor capacity
Severe asthma
title_short Free-IgE as a Predictor of Responsiveness to Omalizumab in Oral Corticosteroid-Dependent Asthma Patients
title_full Free-IgE as a Predictor of Responsiveness to Omalizumab in Oral Corticosteroid-Dependent Asthma Patients
title_fullStr Free-IgE as a Predictor of Responsiveness to Omalizumab in Oral Corticosteroid-Dependent Asthma Patients
title_full_unstemmed Free-IgE as a Predictor of Responsiveness to Omalizumab in Oral Corticosteroid-Dependent Asthma Patients
title_sort Free-IgE as a Predictor of Responsiveness to Omalizumab in Oral Corticosteroid-Dependent Asthma Patients
dc.creator.none.fl_str_mv Domingo, Christian
Monserrate, Daniel-Ross
Ollert, Markus
Pomares, Xavier
Forné Izquierdo, Carles
Del Estal, Jorge
Amengual, María José
author Domingo, Christian
author_facet Domingo, Christian
Monserrate, Daniel-Ross
Ollert, Markus
Pomares, Xavier
Forné Izquierdo, Carles
Del Estal, Jorge
Amengual, María José
author_role author
author2 Monserrate, Daniel-Ross
Ollert, Markus
Pomares, Xavier
Forné Izquierdo, Carles
Del Estal, Jorge
Amengual, María José
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Biomarker
Blood IgE
Clinical response
Free IgE
Omalizumab
Predictor capacity
Severe asthma
topic Biomarker
Blood IgE
Clinical response
Free IgE
Omalizumab
Predictor capacity
Severe asthma
description To date, no biomarkers have been found that are able to predict the clinical response to omalizumab. The aim of this study was to assess whether blood concentration of free Immunoglobulin E (IgE) can predict response to treatment with this monoclonal antibody. In a group of patients who were candidates for omalizumab treatment, forced spirometry and blood IgE were measured at entry and at each six-month visit, and free-IgE blood concentrations were measured at month 6. At month 18, the OMADORE protocol was applied. The complete follow-up lasted 30 months. Patients were considered responders if they met at least one of the following criteria: increase in forced expiratory volume in one second (FEV) at the follow-up visit compared to baseline; reduction in corticosteroid dose at the last visit compared to baseline; reduction in omalizumab dose at the follow-up visit; a positive score on the composite index combining all three criteria. The biomarker used to predict treatment response was the free IgE value and the percentage of free IgE to total IgE measured at visit 1, after six months of omalizumab treatment. The percentage of responders varied according to the parameter used (FEV, omalizumab, corticosteroid dose, and the composite index; 45.2%, 64.5%, 48.4%, and 77.4%, respectively). IgE blockade was around 97% both for the group as a whole and for the subgroups. There were no differences in free IgE values nor in the ratio of free IgE to total IgE between responders and non-responders. These results confirm that there is a group of patients who may benefit from the reduction/withdrawal of omalizumab. Determination of free IgE six months after initiation of omalizumab treatment does not discriminate between responders and non-responders.
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://doi.org/10.3390/ijms26072852
https://hdl.handle.net/10459.1/468789
http://hdl.handle.net/10459.1/468789
url https://doi.org/10.3390/ijms26072852
https://hdl.handle.net/10459.1/468789
http://hdl.handle.net/10459.1/468789
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.3390/ijms26072852
International Journal of Molecular Sciences, 2025, vol. 26, núm. 7, 2852
dc.rights.none.fl_str_mv cc-by (c)The Authors, 2025
Attribution 4.0 International
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
rights_invalid_str_mv cc-by (c)The Authors, 2025
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869418838483795968
score 15,811543

Registos relacionados